X

Trial Profile

AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 May 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OSCAR; OSCAR1
Sponsors Roche

Most Recent Events

13 Sep 2018 Status changed from active, no longer recruiting to completed.
10 May 2018 Planned End Date changed from 1 Aug 2017 to 30 Jun 2018.
10 May 2018 Planned primary completion date changed from 1 Aug 2017 to 30 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com